C
1.41
0.03 (2.03%)
| Previous Close | 1.38 |
| Volume | 11,032 |
| Price / Sales | 1.12 |
| Price / Book | 9.89 |
| 52 Weeks Range |
| Profit Margin | -106.77% |
| Operating Margin (TTM) | -52.24% |
| Diluted EPS (TTM) | -2.64 |
| Quarterly Revenue Growth (YOY) | 49.70% |
| Quarterly Earnings Growth (YOY) | -60.90% |
| Total Debt/Equity (MRQ) | 778.95% |
| Current Ratio (MRQ) | 0.380 |
| Operating Cash Flow (TTM) | -6.40 M |
| Levered Free Cash Flow (TTM) | 10.32 M |
| Return on Assets (TTM) | -17.42% |
| Return on Equity (TTM) | -232.51% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Celularity Inc. | Mixed | Mixed |
AIStockmoo Score
-0.1
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 5.0 |
| Average | -0.13 |
|
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 51.26% |
| % Held by Institutions | 14.66% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| C V Starr & Co Inc | 30 Jun 2026 | 764,069 |
| Biltmore Family Office, Llc | 30 Jun 2026 | 35,000 |
| Keynote Financial Services Llc | 30 Jun 2026 | 29,920 |
| Centerstar Asset Management, Llc | 30 Jun 2026 | 21,000 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |